Am Fam Physician. 2025;112(3):325-326
Author disclosure: No relevant financial relationships.
| Test | Indication | Population | Cost* |
|---|---|---|---|
| EpiSwitch | Screening for prostate cancer | Patients aged 55–69 years who wish to be screened | $950 |
The prostate-specific antigen (PSA) test is the most widely used tool for prostate cancer screening. However, potential harms of this test include false-positive results, biopsy complications, overdiagnosis, psychological harms, and treatment harms.1–6 The US Preventive Services Task Force recommends shared decision-making for PSA-based prostate cancer screening in men aged 55 to 69 years and recommends against PSA-based screening in men 70 years and older.7
Already a member/subscriber?
Log In
Subscribe
From $180- Immediate, unlimited access to all AFP content
- More than 125 CME credits/year
- AAFP app access
- Print delivery available
Issue Access
$59.95- Immediate, unlimited access to this issue's content
- CME credits
- AAFP app access
- Print delivery available
Interested in AAFP membership?
Learn More
